PFE - Moderna CEO Highlights Promising Cancer Vaccine Data: 'Think About The Number Of Lives That Can Be Impacted' | Benzinga
Moderna, Inc. (NASDAQ: MRNA) CEO Stéphane Bancel appeared on CNBC's "Squawk Box" Thursday to discuss the company's promising new cancer vaccine developed in partnership with Merck & Company, Inc. (NYSE: MRK).
What Happened: When combined with Keytruda, Moderna's new vaccine candidate mRNA-4157 (V940) reduced the risk of relapse or death by 49% in melanoma patients and showed a 62% lower risk of the cancer spreading, the Moderna CEO said.
"It's a big day for patients, and we are so excited," Bancel said. "We think it's a huge impact on melanoma, it's one in two people. ...